Bioinformatics & Personalized Medicine



Bioinformatics is an emerging discipline that utilizes a wide array of computational tools designed to extract valuable information contained within genomic data.  The output from these bioinformatic analyses can reveal unique DNA and/or protein sequences that becomes the signature target for a novel diagnostic test.



 EMS supported the Office of Infectious Diseases through a contract for bioinformatics and advanced molecular detection. Our employees assisted 8 federal Principal Investigators with more than 11 different projects in the Division of High-Consequence Pathogens and Pathology – Poxvirus & Rabies Research Branch, Division of Viral Diseases – Measles, Mumps, Rubella, and Herpesvirus Laboratory Branch, Division of Viral Diseases – Pathogen Discovery Program, Division of Viral Hepatitis, Division of Parasitic Diseases and Malaria -Malaria Branch.

One of our senior bioinformaticians presented the results of their work entitled “Rapid Identification of Monkeypox Virus using Tandem Repeats with Insertion, Deletion and SNPs” at the 1st ASM Conference on Rapid Next-Generation Sequencing and Bioinformatic Pipelines for Enhanced Molecular Epidemiologic Investigation of Pathogens in Washington, DC in September 2015. To see the results of this work, please view the poster presentation attached below.









Global Hepatitis & Surveillance Technology (GHOST)



EMS provided vital support toward the development of Global Hepatitis & Surveillance Technology (GHOST) where the genetic makeup of each patient’s Hepatitis C viruses are registered in a patient database. GHOST then combines all the information in its database to produce a “map” of Hepatitis C transmission, linking infections of similar viruses in clusters to identify how the virus has spread.

This web-based platform will help clinicians and epidemiologist access data faster and with less manual processing once the information has been received. It also reduces the cost of molecular testing so that more individuals can be tested and the spread of viral hepatitis can be properly tracked. This model of surveillance may be applied to other infectious diseases in the future. To see the results of this work, please view the poster presentation attached below.









EMS recently formed a partnership with CFDRC and their daughter company, SynVivo. SynVivo develops microfluidic chip technology that recreates the microvascular environment of a patient. Because the cells in a SynVivo chip experiences physical stress from the fluid environment the culture develops in a way that closely resembles a natural system. These cells then show cellular, molecular and drug responses similar to what is observed in vivo.